Cargando…
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
Background. Pancreatic neuroendocrine tumors (NETs) are rare but are frequently diagnosed at advanced stages and require systemic therapy. Patients and methods. This multicenter, open-label, phase II study evaluated sunitinib in Japanese patients with well-differentiated pancreatic NET. Patients rec...
Autores principales: | Ito, Tetsuhide, Okusaka, Takuji, Nishida, Toshirou, Yamao, Kenji, Igarashi, Hisato, Morizane, Chigusa, Kondo, Shunsuke, Mizuno, Nobumasa, Hara, Kazuo, Sawaki, Akira, Hashigaki, Satoshi, Kimura, Nobuyuki, Murakami, Mami, Ohki, Emiko, Chao, Richard C., Imamura, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771378/ https://www.ncbi.nlm.nih.gov/pubmed/23269537 http://dx.doi.org/10.1007/s10637-012-9910-y |
Ejemplares similares
-
Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study
por: Ito, Tetsuhide, et al.
Publicado: (2019) -
Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017) -
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
por: Bang, Yung-Jue, et al.
Publicado: (2010) -
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013) -
A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma
por: Okusaka, Takuji, et al.
Publicado: (2011)